FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
SUWANEE, GA, Dec. 29, 2017 --
SANUWAVE Health, Inc. (OTCQB: SNWV) announced today that the Company has received notice from the United States Food and Drug Administration permitting the marketing of the dermaPACE® system for the treatment of Diabetic Foot Ulcers.
The Company will issue a more comprehensive press release and host a conference call on Tuesday, January 2, 2018, beginning at 11:00AM Eastern Time to discuss the FDA letter and the Company’s plans.
Shareholders and other interested parties can participate in the conference call by dialing 877-407-8033 (U.S.) or 201-689-8033 (international) or via webcast at http://www.investorcalendar.com/event/23276.
A replay of the conference call will be available beginning two hours after its completion through January 16, 2018, by dialing 877-481-4010 (U.S.) or 919-882-2331 (international) and entering Conference ID 23276.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., the dermaPACE system has been approved under FDA’s de novo petition process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food, and industrial markets.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors, or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.
Millennium Park Capital LLC Christopher Wynne 312-724-7845 [email protected] SANUWAVE Health, Inc. Kevin Richardson II Chairman of the Board 978-922-2447 [email protected]
